5-Hydroxydecanoate sodium is a selective ATP-sensitive K+ (KATP) channel blocker (IC50 approximately 30 μM). 5-Hydroxydecanoate sodium is a substrate for mitochondrial outer membrane acyl-CoA synthetase and has anti-oxidant effect.

Physicochemical Properties

Molecular Formula	C10H19NAO3
Molecular Weight	210.25
Exact Mass	210.123
CAS #	71186-53-3
PubChem CID	23676659
Appearance	White to off-white solid powder
Boiling Point	320.8ºC at 760 mmHg
Flash Point	162ºC
LogP	0.847
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	8
Heavy Atom Count	14
Complexity	139
Defined Atom Stereocenter Count	0
InChi Key	YNAGNECWEKMWRM-UHFFFAOYSA-M
InChi Code	InChI=1S/C10H20O3.Na/c1-2-3-4-6-9(11)7-5-8-10(12)13;/h9,11H,2-8H2,1H3,(H,12,13);/q;+1/p-1
Chemical Name	sodium;5-hydroxydecanoate
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	IC50: ~30 μM (KATP)
ln Vitro	The protective effect of penehyclidine hydrochloride (PHC) pretreatment on anoxia/reoxygenation (A/R)-induced H9c2 cell damage was eliminated by 5-Hydroxydecanoate (5-HD) treatment. 5-Hydroxydecanoate inhibits PHC's inhibitory action on ROS generation and Ca2+ overload. 5-Hydroxydecanoate encourages Cyt-C to be released into the cytoplasm from mitochondria. 5. Hydroxydecanoate reduces PHC's anti-apoptotic activity. Following PHC treatment, there was a notable rise in Bcl-2 levels and a significant drop in Bax and cleaved caspase-3 levels. 5. Pretreatment with hydroxydecanoate may counteract the impact of PHC on its expression level. Five-hydroxydecanoate inhibits PHC's impact on KATP channels [1].
ln Vivo	5-Hydroxydecanoate (100 μM) therapy prevented the effects of ischemia preconditioning (IPC) on contractile recovery in rats, while leaving intact its effects on contracture, lactate generation, glycogenolysis, and viable tissue [3].
References	[1]. Penehyclidine hydrochloride protects against anoxia/reoxygenation injury in cardiomyocytes through ATP-sensitive potassium channels, and the Akt/GSK-3β and Akt/mTOR signaling pathways. Cell Biol Int. 2020 Jun;44(6):1353-1362. [2]. 5-Hydroxydecanoate and coenzyme A are inhibitors of native sarcolemmal KATP channels in inside-out patches. Biochim Biophys Acta. 2010 Mar;1800(3):385-91. [3]. Effects of 5-hydroxydecanoate and ischemic preconditioning on the ischemic-reperfused heart of fed and fasted rats. J Physiol Biochem. 2005 Sep;61(3):447-56.

Solubility Data

Solubility (In Vitro)

DMSO: 12.5 mg/mL (59.45 mM) H2O: 10 mg/mL (47.56 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 1.25 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (5.95 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 6.25 mg/mL (29.73 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	4.7562 mL	23.7812 mL	47.5624 mL
	5 mM	0.9512 mL	4.7562 mL	9.5125 mL
	10 mM	0.4756 mL	2.3781 mL	4.7562 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.